Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines.
Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, Benicar HCT, Azor and Tribenzor.
The accord, under which the Tokyo-based company didn't admit wrongdoing, comes more than two years after it paid $39 million to resolve the U.S. government's allegation that it had paid illegal kickbacks to doctors who prescribed the medicines.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.